Literature DB >> 2432615

Protein abnormalities in adult respiratory distress syndrome, tuberculosis, and cystic fibrosis sera.

M Emmett, J L Miller, A J Crowle.   

Abstract

Crossed immunoelectrophoresis (X-IEP) revealed several abnormalities in serum proteins from patients with adult respiratory distress syndrome (ARDS), tuberculosis (TB), and cystic fibrosis (CF). The two quite different kinds of pulmonary disease, one acute (ARDS) and the other chronic (TB and CF) exhibited serum changes specific for each disease and abnormalities associated with inflammation and pathogenesis, in general. In ARDS sera, most proteins were extremely low, presumably due to leakage into the lungs through damaged tissue, while the acute-phase proteins, orosomucoid, alpha 1-antitrypsin, alpha 1-antichymotrypsin, and haptoglobin, were markedly high when compared to the overall protein pattern. The extremely high alpha 1-antichymotrypsin values were not seen in corresponding TB and CF sera. Numerous TB patients had elevated alpha 1-antitrypsin, alpha 1-antichymotrypsin, and haptoglobin, but only the alpha 1-antitrypsin population mean was significantly different from normal. Gc-globulin, ceruloplasmin, and beta-lipoprotein were higher and alpha 1-lipoprotein and inter-alpha-trypsin inhibitor lower than normal. All other quantitative serum changes were not statistically significant. Surprisingly, all TB patients belonged to the Gc-1-1 genotype in contrast to the Gc-1-1, Gc-1-2, Gc-2-2 polymorphisms of the other populations. CF homozygote sera revealed statistically significant increases in the acute-phase proteins, alpha 1-antitrypsin, alpha 1-antichymotrypsin, and haptoglobin, while orosomucoid, transferrin, IgA, and IgG tended to be higher than normal. The tendency for higher levels of transferrin indicated possible iron deficiency in some patients. In contrast, prealbumin, alpha 1-lipoprotein, and inter-alpha-trypsin inhibitor were significantly depressed in CF patients. CF heterozygotes shared the decrease of alpha 1-lipoprotein with the patients while exhibiting small but significant depressions of alpha 2-macroglobulin and IgG. Though not statistically significant, lowered concentrations of alpha 1-antitrypsin were evident for the heterozygotes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432615     DOI: 10.3181/00379727-184-42448

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  6 in total

1.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

2.  Vitamin D-binding protein is inversely associated with the incidence of gastrointestinal and ear infections in school-age children.

Authors:  K M Palframan; S L Robinson; M Mora-Plazas; C Marin; E Villamor
Journal:  Epidemiol Infect       Date:  2018-07-30       Impact factor: 4.434

3.  Proteomic profiling of serum from patients with tuberculosis.

Authors:  Sang Hoon Song; Minje Han; Yang Seon Choi; Ki Soon Dan; Man Gil Yang; Junghan Song; Sung Sup Park; Jae Ho Lee
Journal:  Ann Lab Med       Date:  2014-08-21       Impact factor: 3.464

4.  Alterations in the human lung proteome with lipopolysaccharide.

Authors:  Russell P Bowler; Nichole Reisdorph; Richard Reisdorph; Edward Abraham
Journal:  BMC Pulm Med       Date:  2009-05-11       Impact factor: 3.317

5.  Vitamin d-binding protein levels in plasma and gingival crevicular fluid of patients with generalized aggressive periodontitis.

Authors:  Xin Zhang; Huanxin Meng; Li Xu; Li Zhang; Dong Shi; Xianghui Feng; Ruifang Lu; Zhibin Chen
Journal:  Int J Endocrinol       Date:  2014-05-12       Impact factor: 3.257

6.  Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome.

Authors:  Malgorzata Wygrecka; Rory E Morty; Philipp Markart; Sandip M Kanse; Peter A Andreasen; Troels Wind; Andreas Guenther; Klaus T Preissner
Journal:  J Biol Chem       Date:  2007-05-31       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.